

**CLAIMS AMENDMENTS**

Please amend the claims as follow:

Claims 1-41 (cancelled)

42. (Currently amended) A pharmaceutical composition comprising an isolated human monoclonal antibody capable of binding oligodendrocytes and capable of inducing remyelination selected from the group consisting of ~~mAb-SHlgM22 (LYM-22)~~ antibody having a heavy chain sequence comprising the heavy chain variable region sequence of SEQ ID NO:7 and a light chain sequence comprising the light chain variable region sequence of SEQ ID NO:9, IgM monomers thereof, active Fab, Fab', F(ab')<sub>2</sub> or F(v) fragments thereof, and recombinant antibodies derived therefrom having a heavy chain sequence comprising the heavy chain variable region sequence of SEQ ID NO:7 and a light chain sequence comprising the light chain variable region sequence of SEQ ID NO:9 and a pharmaceutically acceptable carrier, vehicle or diluent.

43. (Currently amended) A pharmaceutical composition comprising isolated ~~mAb-SHlgM22 (LYM22)~~ antibody capable of binding oligodendrocytes and capable of inducing remyelination having a heavy chain sequence comprising the heavy chain variable region sequence of SEQ ID NO:7 and a light chain sequence comprising the light chain variable region sequence of SEQ ID NO:9 and a pharmaceutically acceptable carrier, vehicle or diluent.

Claim 44 (cancelled)

Claim 45 (cancelled)

Claim 46 (cancelled)

Claim 47 (cancelled)

Claim 48 (cancelled)

Claim 49 (cancelled)

Claim 50 (cancelled)

US Serial No.

10/010,729

Claim 51 (cancelled)

Claim 52 (cancelled)

Claim 53 (cancelled)

Claim 54 (cancelled)

Claim 55 (cancelled)

Claim 56 (cancelled)

Claim 57 (cancelled)

Claim 58 (cancelled)

Claim 59 (cancelled)

Claim 60 (cancelled)

Claim 61 (cancelled)

Claim 62 (cancelled)

Claim 63 (cancelled)

Claim 64 (cancelled)

Claim 65 (cancelled)

Claim 66 (cancelled)

Claim 67 (cancelled)

Claim 68 (cancelled)

Claim 69 (cancelled)

Claim 70 (cancelled)

Claim 71 (cancelled)

Claim 72 (cancelled)

PATENT

1199-1-005CIP2

73. (previously presented) A pharmaceutical composition comprising an amount of an isolated antibody polypeptide capable of binding oligodendrocytes and capable of inducing remyelination produced by the method of

(a) introducing a vector comprising a DNA molecule comprising a DNA sequence encoding an antibody polypeptide having a heavy chain sequence comprising the amino acid sequence set out in FIGURE 35 (SEQ ID NO:7) and a light chain sequence

comprising the amino acid sequence set out in FIGURE 36 (SEQ ID NO:9)  
into a suitable host cell;  
(b) culturing the resulting host cell so as to produce the polypeptide;  
(c) recovering the polypeptide produced in step (b); and  
(d) purifying the polypeptide recovered in step (c);  
and a pharmaceutically acceptable carrier, vehicle or diluent.

Claim 74 (cancelled)

Claim 75 (cancelled)

Claim 76 (cancelled)

Claim 77 (cancelled)

Claim 78 (cancelled)

Claim 79 (cancelled)

Claim 80 (cancelled)

Claim 81 (cancelled)

Claim 82 (cancelled)

Claim 83 (cancelled)

Claim 84 (cancelled)

Claim 85 (cancelled)

Claim 86 (cancelled)

Claim 87 (cancelled)

Claim 88 (cancelled)

Claim 89 (cancelled)

Claim 90 (cancelled)

91. (Previously presented) An isolated antibody capable of binding oligodendrocytes and capable of inducing remyelination and having a heavy and light chain, wherein the heavy chain sequence comprises the amino acid sequence set out in FIGURE 35 (SEQ ID NO:7) and the light chain sequence comprises the amino acid sequence set out in FIGURE 36 (SEQ ID NO:9), or

US Serial No.

10/010,729

PATENT

1199-1-005CIP2

active Fab, Fab', F(ab')<sub>2</sub> or F(v) fragments thereof capable of binding oligodendrocytes and capable of inducing remyelination.

92. (Previously presented) An isolated antibody capable of binding oligodendrocytes and capable of inducing remyelination having a heavy and light chain, wherein the heavy chain sequence comprises the heavy chain variable region sequence as set out in FIGURE 35 (SEQ ID NO:7).

93. (Previously presented) An isolated antibody capable of binding oligodendrocytes and capable of inducing remyelination having a heavy and light chain, wherein the light chain sequence comprises the light chain variable region sequence as set out in FIGURE 36 (SEQ ID NO:9).

94. (New) An isolated monoclonal antibody capable of binding oligodendrocytes and capable of inducing remyelination selected from the group consisting of mAb sHIgM22 (LYM 22) antibody (ATCC Accession No. PTA-8671), IgM monomers thereof, active Fab, Fab', F(ab')<sub>2</sub> or F(v) fragments thereof, and recombinant antibodies derived therefrom.

95. (New) A pharmaceutical composition comprising the isolated antibody of Claim 94 and a pharmaceutically acceptable carrier, vehicle or diluent.